All-transretinoic acid combined with arsenious acid and chemotherapy in the treatment of acute promyelocytic leukemia patients with 10 years for survival

VernacularTitle:维A酸、亚砷酸联合化疗治疗急性早幼粒细胞白血病的10年生存情况观察
Author: Yanshun ZHANG ; Jin WANG ; Yong WANG
Publication Type:Journal Article
Keywords: Leukemia promyelocytic acute; All -transretinoic acid; Arsenious acid
From: Chinese Journal of Primary Medicine and Pharmacy 2016;23(17):2645-2648
CountryChina
Language:Chinese
Abstract: Objective To study the curative effect and characteristics of all -transretinoic acid (ATRA) and arsenic acid (As2 O3 )combination chemotherapy for acute promyelocytic leukemia (APL).Methods ATRA (30 -60mg/d),As2 O3 (0.1%As2 O3 d1 -28),chemotherapy(anthracycline -based chemotherapy regimens and homoharringtonine -based chemotherapy regimens or high -doses of cytosine arabinoside and small -doses of metho-trexate)were used alternately 4 -5 cycles.Results 12 cases had complete response(CR),CR rate was 100%,first cases and relapse cases all got CR,the median time needed 30 days to get CR.Follow -up deadline,all cases 10 year disease -free survival (DFS )rate was 100%,all reexamination minimal residual disease (MRD)was negative. Conclusion Using this method to treat adult APL,the CR rate is high,has less adverse reaction,and did not produce resistance phenomenon.It can be used for APL consolidation and maintenance therapy.This is one of the ways that can be recommended in the treatment.